title: Metabolic screening and postnatal glucose homeostasis in the newborn.
abstract: Although individual metabolic diseases are relatively uncommon, inherited metabolic diseases collectively represent a more common cause of disease in the neonatal period than is generally appreciated. Newborn screening is among the most successful public health programs today. Every day, newborns considered to be at risk for hypoglycemia are screened. The definition of clinically significant hypoglycemia remains among the most confused and contentious issues in neonatology. There are 2 "competing" methods of defining hypoglycemia that suggest very different levels for management: one based on metabolic-endocrinologic hormones and another that uses outcome data to determine threshold levels of risk.
authors.affiliation: Division of Neonatal Medicine, Department of Pediatrics, University of Louisville, 571 South Floyd Street, Suite 342, Louisville, KY 40202, USA. Electronic address: david.adamkin@louisville.edu.
authors.forename: David H
authors.initials: DH
authors.lastname: Adamkin
mesh_terms: D000138:Acidosis / Q000175:diagnosis; D000222:Adaptation, Physiological; D005947:Glucose / Q000378:metabolism*; D006706:Homeostasis; D006801:Humans; D007003:Hypoglycemia / Q000151:congenital / Q000175:diagnosis; D007231:Infant, Newborn; D008661:Metabolism, Inborn Errors / Q000175:diagnosis / Q000378:metabolism; D015997:Neonatal Screening / Q000379:methods* / Q000592:standards; D053719:Tandem Mass Spectrometry
chemical_list: D005947:Glucose
keywords: Hypoglycemia screening and management; Newborn metabolic screening; Tandem mass spectrometry